Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29763559 | 1.00 | FABP5 (0.39) | FABP5FABP7EPHX2KMT2ACASP3 | |
| SCHEMBL29474439 | 1.00 | FABP5 (0.39) | FABP5FABP7EPHX2KMT2ACASP3 | |
| SCHEMBL29201750 | 1.00 | FABP5 (0.39) | FABP5FABP7EPHX2KMT2ACASP3 | |
| SCHEMBL1905118 | 0.87 | FABP5 (0.44) | FABP5FABP7EPHX2KMT2ACASP3 | |
| SCHEMBL5233109 | 0.86 | FABP5 (0.43) | FABP5FABP7EPHX2KMT2ACASP3 | |
| SCHEMBL18301546 | 0.86 | GLI1 (0.41) | FABP5FABP7EPHX2 | |
| SCHEMBL5494109 | 0.84 | FABP5 (0.43) | FABP5FABP7EPHX2KMT2ACASP3 | |
| SCHEMBL31054358 | 0.84 | PPARG (0.40) | FABP5FABP7EPHX2KMT2AMDM4 | |
| SCHEMBL28916981 | 0.83 | CHRNB2 (0.40) | FABP5FABP7EPHX2KMT2ACASP3 | |
| SCHEMBL29713658 | 0.83 | CHRNB2 (0.40) | FABP5FABP7EPHX2KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | Bicyclerd Limited (GB) | 2025-08-14 | — | — | US | disclosed |
| US-20250230191-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | BICYCLETX LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| US-12318454-B2 | Bicyclic peptide ligands specific for MT1-MMP | Bicyclerd Limited (GB) | 2025-06-03 | — | — | US | disclosed |
| US-20250057993-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS | Universität Heidelberg (DE) | 2025-02-20 | — | — | US | disclosed |
| CN-119431260-A | Targeting prostate specific membranes radiolabeled compounds for antigens | 省卫生服务机构 | 2025-02-14 | — | — | CN | disclosed |
| EP-3452096-B1 | BICYCLIC PEPTIDE-TOXIN CONJUGATES SPECIFIC FOR MT1-MMP | BICYCLERD LTD (GB) | 2025-01-29 | — | — | EP | disclosed |
| EP-4473980-A2 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS | Universität Heidelberg (DE) | 2024-12-11 | — | — | EP | disclosed |
| CN-114401947-B | Targeting prostate specific membranes radiolabeled compounds for antigens | 省卫生服务机构 | 2024-11-29 | — | — | CN | disclosed |
| CN-116217505-B | Novel marker targeting agents for diagnosis or treatment of cancers expressing prostate specific membrane antigen | 南京医科大学 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024193724-A1 | NEW LABELING TARGETING AGENT FOR DIAGNOSING OR TREATING PROSTATE-SPECIFIC MEMBRANE ANTIGEN EXPRESSING CANCER | 南京医科大学 | 2024-09-26 | — | — | WO | disclosed |
| EP-0999220-A2 | Low molecular weight peptidomimetic growth hormone secretagogues | Genentech, Inc. (US) | 2000-05-10 | — | — | EP | disclosed |
| US-6034216-A | Low molecular weight peptidomimetic growth hormone secretagogues | GENENTECH INC. (US) | 2000-03-07 | — | — | US | disclosed |
| WO-1999065932-A1 | TETRAPEPTIDES, ANALOGS AND PEPTIDOMIMETICS WHICH BIND SELECTIVELY MAMMALIAN OPIOID RECEPTORS | SEPRACOR, INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999011657-A1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | PROTEUS MOLECULAR DESIGN LTD. (GB) | 1999-03-11 | — | — | WO | disclosed |
| WO-1999011658-A1 | META-BENZAMIDINE DERIVATIVES AS SERIN PROTEASE INHIBITORS | PROTEUS MOLECULAR DESIGN LTD. (GB) | 1999-03-11 | — | — | WO | disclosed |
| US-5798337-A | USED TO PROMOTE GROWTH IN MAMMALS EITHER ALONE OR IN COMBINATION WITH OTHER GROWTH PROMOTING COMPOUNDS | GENENTECH, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| US-5710129-A | Inhibitors of SH2-mediated processes | ARIAD PHARMACEUTICALS, INC. (US) | 1998-01-20 | — | — | US | disclosed |
| EP-0792289-A1 | LOW MOLECULAR WEIGHT PEPTIDOMIMETIC GROWTH HORMONE SECRETAGOGUES | GENENTECH, INC. (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1997031016-A2 | NEW INHIBITORS OF SH2-MEDIATED PROCESSES | ARIAD PHARMACEUTICALS, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| WO-1996015148-A2 | LOW MOLECULAR WEIGHT PEPTIDOMIMETIC GROWTH HORMONE SECRETAGOGUES | GENENTECH, INC. (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230191-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | MMP11, MMP3, ANPEP | FABP5 1749/4885FABP7 747/4885EPHX2 2634/4885 |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | MMEL1, MMP3, TIMP3 | FABP5 1547/4885FABP7 1488/4885EPHX2 3396/4885 |
| US-12318454-B2 | Bicyclic peptide ligands specific for MT1-MMP | MMEL1, MMP3, TIMP3 | FABP5 1547/4885FABP7 1488/4885EPHX2 3396/4885 |
| US-20250057993-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS | KLK3, FOLH1, PSMA3 | FABP5 2421/4885FABP7 2262/4885EPHX2 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.